The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C.
- Who it may be relevant to
- Registry conditions: HCV Infection, HCV Elimination. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an: A 10-Year Retrospective Study
Overview
The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women. To understand the epidemiological changes and status of hepatitis C virus (HCV) infection in pregnant women in Shaanxi province in recent 10 years, and to analyze the main influencing factors of hepatitis C infection in pregnant women.
Interventions
- Procedure Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C
Initiated Standard DAA treatment among HCV RNA positive patients.
Primary outcome measures
- Relink rate [Time frame: From enrollment to the end of treatment at 12 weeks]
Eligibility criteria
Inclusion criteria
- Pregnant women or parturient women confirmed by blood HCG test.
- Patients aged 18 years old and above.
- Patients with HCV antibody seropositive or HCV RNA positive from 2014-2023.
Exclusion criteria
- Patients without valid telephone numbers.
- Duplicate records: For duplicate records of the same pregnant woman, only one record should be kept.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06952036 · XJTU1AF2024LSYY-413